Vitrolife interim report january - march 2004

Vitrolife interim report january - march 2004

·Core business net sales increased by 14 per cent and amounted to SEK 29,5 million (25,9), corrected for currency effects the increase amounted to 18 per cent.

·The group's gross margin improved to 69 per cent (62).

·Operating result improved and amounted to SEK 5,2 million (-2,2).

·Net result improved and amounted to SEK 6,0 million (-0,6). Result per share SEK 0,32 (-0,03).

·During the first quarter Vitrolife took over the sales in USA and Canada from distributors.

 CEO: Dr. Magnus Nilsson
 Tel: +46 31 721 80 00 
 Mobile +46 708 22 80 61
 [email protected]

Acting CFO and IR agent: Anders Sävfält
Tel: +46 31 721 80 00
[email protected]

Vitrolife is a global biomedical corporation that works with products for cell and tissue technology. The Vitrolife group consists of the parent company, Vitrolife AB (Publ) and two wholly owned subsidiaries: Vitrolife Sweden AB (Gothenburg, Sweden), Vitrolife Inc. (Denver, Colorado). The group's operations focused on three geographic areas.

· Europe/Middle East
· The Americas
· Rest of the World

Vitrolife's business concept is to develop, produce and sell advanced products and systems for the preparation, cultivation, preservation and support of cells, tissues and organs.

Report